Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.62 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.62 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751057 | 0.93 | SCN9A (0.66) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3943038 | 0.93 | SCN9A (0.61) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3753733 | 0.91 | ALDH1A1 (0.62) | SCN9ASCN5AKCNH2KCNA5P2RX7 | |
| SCHEMBL3759970 | 0.89 | SCN9A (0.65) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3750116 | 0.88 | SCN9A (0.52) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3950452 | 0.87 | SCN9A (0.67) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3950604 | 0.86 | SCN9A (0.59) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3756567 | 0.86 | SCN9A (0.76) | SCN9ASCN5AKCNH2KCNA5KCNQ2 | |
| SCHEMBL3754120 | 0.86 | P2RX7 (0.59) | SCN9ASCN5AKCNH2KCNA5P2RX7 | |
| SCHEMBL3955691 | 0.86 | SCN9A (0.82) | SCN9ASCN5AKCNH2KCNA5KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | claimed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | SCN9A 119/4885SCN5A 48/4885KCNH2 2/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | SCN9A 177/4885SCN5A 26/4885KCNH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.